Keyphrases
Sentinel Lymph Node
50%
Human Epidermal Growth Factor Receptor 2 (HER2)
44%
Breast Cancer Patients
43%
Breast Cancer
38%
Tumor
37%
One-step nucleic Acid Amplification
30%
Neoadjuvant Therapy
29%
Trastuzumab
23%
Eukaryotic Translation Initiation Factor 4E (eIF4E)
23%
Axillary Lymph Node Dissection
22%
Total Tumor Load
21%
4E-BP1
21%
HER2-positive Breast Cancer
17%
Chemotherapy
17%
Non-sentinel Lymph Node Metastasis
16%
Cell Signaling
15%
Primary Tumor
14%
Early Breast Cancer Patients
14%
Tumoral
14%
Circulating Tumor DNA (ctDNA)
14%
Tumor Heterogeneity
14%
P95HER2
13%
Genetic Modification
13%
Neoadjuvant Chemotherapy
13%
Ki-67
11%
Positive Sentinel Lymph Node
11%
Sentinel Lymph Node Biopsy
11%
Genetic Heterogeneity
11%
HER2-targeted Therapy
11%
Disease-free Survival
10%
HER2-positive
10%
Metastasis
10%
Massively Parallel Sequencing
10%
Actionable mutations
10%
Therapeutic Target
9%
Glioblastoma
9%
Residual Disease
9%
Brain Tumor
9%
Tumor Protein p53 (TP53)
9%
Human Epidermal Growth Factor Receptor 2-positive Breast Cancer
9%
Signaling Factors
8%
Clinical Data
8%
Primary Breast Cancer
8%
Intratumor Genetic Heterogeneity
8%
Nomogram
8%
Immunohistochemistry
8%
Protein Expression
8%
Terminal Fragment
8%
Patients with Breast Cancer
8%
Molecular Assay
8%
Medicine and Dentistry
Breast Cancer
100%
Neoplasm
81%
Sentinel Lymph Node
35%
Nucleic Acid Amplification
24%
Malignant Neoplasm
24%
Epidermal Growth Factor Receptor 2
23%
Neoadjuvant Therapy
23%
Gamma Urogastrone
22%
Human Epidermal Growth Factor Receptor 2 Positive Breast Cancer
21%
Axillary Lymph Node
21%
Retroperitoneal Lymph Node Dissection
20%
Genetic Heterogeneity
19%
Primary Tumor
17%
Metastatic Carcinoma
17%
Signal Transduction
16%
Initiation Factor 4E
16%
Circulating Tumor DNA
14%
Tumour Heterogeneity
14%
Neoadjuvant Chemotherapy
13%
Trastuzumab
13%
Proteomics
11%
Sentinel Lymph Node Biopsy
10%
Sentinel Lymph Node Metastasis
10%
BRCA1
10%
Intracranial Tumor
9%
Chemotherapy
9%
Prognostic Factor
9%
Immunohistochemistry
9%
Adjuvant Therapy
8%
Cancer Therapy
8%
Immunity
8%
Carcinoma
8%
Carboxy Terminal Sequence
8%
Hypoxia
8%
Estrogen Receptor
8%
Breast Tumor
8%
Disease Free Survival
7%
Peroperative Echography
7%
PARP Inhibitor
7%
Cancer Types
7%
Triple Negative Breast Cancer
7%
Cancer Stem Cell
7%
Lymph Node Metastasis
7%
Epidermal Growth Factor Receptor
7%
Minimal Residual Disease
7%
Metastatic Breast Cancer
7%
Glioblastoma
7%
Brain Metastasis
7%
Initiation Factor 4E Binding Protein 1
7%
Endometrium Carcinoma
7%